methyclothiazide
Trade name: enduron
Approved
Oct 21, 1960
Methyclothiazide, a diuretic-antihypertensive agent, is a member of the benzothiadiazine (thiazide) class of drugs. Methyclothiazide has a per mg natriuretic activity approximately 100 times that of the prototype thiazide, chlorothiazide. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic/natriuretic effects. Like other benzothiadiazines, methyclothiazide also has antihypertensive properties, and may be used for this purpose either alone or to enhance the antihypertensive action of other drugs. Methyclothiazide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis. As a diuretic, methyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like methyclothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of methyclothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. Methyclothiazide is used in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Also used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 11 marketing orgs
Timeline
1960s
1970s
- Sep 30, 1975
Medpointe — NDA Secondary Org
1980s
- Jun 3, 1982
Ivax — Marketing Organization
- Aug 17, 1982
Mylan — Marketing Organization
- Aug 17, 1982
PHARMOBEDIENT — Marketing Organization
- Sep 6, 1984
Watson Pharmaceuticals — Marketing Organization
- Feb 12, 1986
Par Pharmaceuticals — Marketing Organization
- Aug 18, 1988
Fosun — Marketing Organization
- Aug 18, 1988
Chartwell Pharmaceuticals — Marketing Organization
Indications
Approved for
Mechanism of action
SLC12A3 inhibitor
Combination products
diutensen-r
with reserpine
enduronyl
with deserpidine
Also known as enduronyl forte
eutron
with pargyline
Approval history
- approvedOct 21, 1960
Chemistry & pharmacology
SMILES
CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O- Mol. weight
- 360.237 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaMethyclothiazide ↗
- NCATSL3H46UAC61 ↗
- ChEMBLCHEMBL1577 ↗
Also known as
- aquatensen
- aquatensen
- enduron
- enduron
- enduron
- enduron
- methychlothiazide
- methychlothiazide
- methychlothiazide
- methychlothiazide
- methychlothiazide
- methychlothiazide
- methyclothiazid
- methyclothiazide
- methyclothiazide
- methyclothiazide
- methyclothiazide
- methyclothiazide
- methyclothiazide
- methyclothiazide
- methylclothiazide
- methylclothiazide
Organizations
Marketing (13)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AbbVie | For profit | NDA2 | Oct 21, 1960 |
| AbbVie | For profit | NDA | Oct 21, 1960 |
| Abbott | For profit | MKTG | Aug 1, 1961 |
| Abbott | For profit | NDA2 | Aug 1, 1961 |
| Chartwell Pharmaceuticals | For profit | MKTG | Aug 18, 1988 |
| Fosun | For profit | MKTG | Aug 18, 1988 |
| Ivax | For profit | MKTG | Jun 3, 1982 |
| Medpointe | For profit | NDA2 | Sep 30, 1975 |
| Mylan | For profit | MKTG | Aug 17, 1982 |
| PHARMOBEDIENT | For profit | MKTG | Aug 17, 1982 |
| Par Pharmaceuticals | For profit | MKTG | Feb 12, 1986 |
| Upsher-Smith Laboratories | For profit | MKTG | — |
| Watson Pharmaceuticals | For profit | MKTG | Sep 6, 1984 |